Mark Zuckerberg-Backed AI Startup Takes Over Parkinson’s Treatment From the Maker of Ozempic

The deal gives Cellular Intelligence control of a clinical-stage therapy designed to restore the dopamine-producing nerve ...

Why one Parkinson’s treatment may not work for every patient

New machine learning study uncovers hidden forms of Parkinson’s disease, which researchers say could help explain why the ...

Drive Toward A Cure Fuels Parkinson’s Research And Patient Care

Every Drive Toward a Cure car rally is more than just a drive—it’s a journey fueled by passion, friendship, and a shared ...

Immune protein emerges as possible target to slow Parkinson's progression

Monoclonal antibodies can block a key immune-related protein that drives the spread of brain cell damage in Parkinson's ...

Parkinson's tremors cure could be found in a bean

Parkinson’s disease affects more than 1.1 million people in the U.S., according to the Parkinson’s Foundation.
Observer-Reporter

Treatments for Parkinson’s disease are advancing

Parkinson’s disease currently affects nearly one million Americans with no specific known cause and no cure. Treatments have come a long way over the past few decades focusing on managing symptoms and ...

Zuckerberg backed-Cellular Intelligence acquires Novo Nordisk's Parkinson's cell therapy

Meta CEO Mark Zuckerberg backed-Cellular Intelligence has acquired Danish drugmaker Novo Nordisk's cell therapy candidate for ...

Rebecca Crews Talks About Getting New Parkinson’s Disease Treatment

Rebecca King Crews talks about how husband Terry first told her about a new FDA approval for focused ultrasound for treating ...
UVA Today

Q&A: What new drug is the FDA reviewing to treat Parkinson’s disease?

The U.S. Food and Drug Administration is reviewing a new Parkinson’s disease drug called tavapadon that could give people with the disease more control over their movements. If approved, it would be ...